Adherence to highly active antiretroviral therapy in Spain. A meta-analysis

Gaceta Sanitaria

Volumn 25, Issue 4, 2011, Pages 282-289

  Ortego, Carmen ^a   Huedo Medina, Tania Bibiana ^b   Vejo, Javier ^a   Llorca, Francisco Javier ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Adherence; AIDS HIV; HAART; Meta analysis; Observational studies

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; FACTUAL DATABASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; META ANALYSIS; PATIENT COMPLIANCE; SOCIOECONOMICS; SPAIN; STATISTICS; THEORETICAL MODEL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATABASES, FACTUAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MODELS, THEORETICAL; SOCIOECONOMIC FACTORS; SPAIN; VIRAL LOAD;

EID: 79960847760     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/j.gaceta.2010.10.016     Document Type: Article

References (82)

1. Hogg R.S., Heath K.V., Yip B., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
2. Mocroft A., Ledergerber B., Katlama C., et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
3. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
4. Santos E., Fuertes A. Efectos adversos de los fármacos antirretrovirales. Fisiopatología, manifestaciones clínicas y tratamiento. An Med Intern 2006, 23:338-344.
5. Carpenter C.C., Cooper D.A., Fischl M.A., et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
6. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
7. Bangsberg D.R., Acosta E.P., Gupta R., et al. Adherence-resistence relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006, 20:223-231.
8. Bangsberg D.R. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibidor therapy can lead to viral suppression. Clin Infect Dis 2006, 43:930-941.
9. Lima V.D., Harrigan R., Murray M., et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008, 22:2371-2380.
10. Martin M., Del Cacho E., Codina C., et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008, 24:1263-1268.
11. Bangsberg D.R., Charlebois E.D., Grant R.M., et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003, 17:1925-1932.
12. Harrigan P.R., Hogg R.S., Dong W.W., et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005, 191:339-347.
13. Lima V.D., Harrigan R., Bangsberg D.R., et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009, 50:529-536.
14. Plan multisectorial frente a la infección por VIH y el sida. España 2008-2012 2008, Ministerio de Sanidad y Consumo, Ministerio de Sanidad y Consumo, Centro de Publicaciones, Madrid.
15. Instituto de Salud Carlos III. Vigilancia epidemiológica del sida en España. Registro Nacional de casos de sida. 2009 Informe semestral n° 1. Año 2009; 1.
16. WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2008. Geneve; 2009.
17. Quirós R. Políticas farmacéuticas: su repercusión en la prestación farmacéutica. Revista Administración Sanitaria 2008, 6:633-639.
18. Tornero C., Cuenca A., Santamaría A., et al. Distribución del gasto farmacéutico en medicación antirretroviral. An Med Intern 2004, 21:269-271.
19. Abellán J., Garrote M., Pulido F., et al. Evaluation of adherence to a triple antiretroviral therapy in HIV-positive patients. Eur J Intern Med 1999, 10:202-205.
20. Alcoba M., Cuevas M.J., Pérez-Simón M.R., et al. Assessment of adherence to triple antiretroviral treatment including indinavir: role of the determination of plasma levels of indinavir. J Acquir Immune Defic Syndr 2003, 33:253-258.
21. Codina C., García F., Gatell J.M., et al. Comparación de tres métodos de cálculo de adherencia en pacientes con tratamiento antirretroviral. Enferm Infecc Microbiol Clin 2002, 20:484-490.
22. Escobar I. Desarrollo y evaluación de un programa de intervención para la mejora de la adherencia al tratamiento antirretroviral en pacientes con infección VIH: determinación del perfil del paciente incumplidor en un área de salud 2003, Dpto. Farmacia y Tecnología Farmacéutica. Universidad Complutense de Madrid.
23. Fumaz C.R., Muñoz-Moreno J.A., Molto J., et al. Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. AIDS Care 2008, 20:796-805.
24. García de Olalla P., Knobel H., Carmona A., et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002, 30:105-110.
25. Gordillo V., Del Amo J., Soriano V., et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999, 13:1763-1769.
26. Ines S.M., Moralejo L., Marcos M., et al. Adherence to highly active antiretroviral therapy in HIV-infected inmates. Curr HIV Res 2008, 6:164-170.
27. Knobel H., Alonso J., Casado J.L., et al. Validation of a simplified medication adherence questionaire in a large cohorte of HIV-infected patients: the GEEMA study. AIDS 2002, 605-613.
28. Knobel H., Vallecillo G., Guelar A., et al. Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients. HIV Clin Trials 2004, 5:65-73.
29. Ladero Martín L., Orejudo Hernández S., Carrobles Isabel J., et al. Consumo de drogas y adherencia a la terapia antirretroviral de pacientes en programa de mantenimiento con metadona. Adicciones 2005, 17:203-214.
30. Martín M.T., Del Cacho E., López E., et al. Reacciones adversas del tratamiento antirretroviral. Relación entre los síntomas percibidos y el cumplimiento terapéutico. Med Clin 2007, 4:127-133.
31. Martín J., Escobar I., Rubio R., et al. Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIV. HIV Clin Trials 2001, 2:31-37.
32. Martín Sánchez V., Ortega Valín L., Pérez Simón M.R., et al. Factores predictores de no adherencia al tratamiento antirretroviral de gran actividad. Enferm Infecc Microbiol Clin 2002, 20:491-497.
33. Morillo R., Abdel L., Márquez E., et al. Análisis de las causas de suspensión del régimen antirretroviral simplificado abacavir, lamivudina y zidovudina. Farm Hosp 2005, 29:164-170.
34. Ortega L., Cuevas M.J., Pérez R., et al. Factores predictores de carga viral detectable en pacientes en tratamiento antirretroviral de gran actividad. Med Clin 2004, 123:45-49.
35. Remor E. Infección por VIH y sida: características psicológicas y adhesión al tratamiento 2000, Dpto. Psicología Biológica y de la Salud. Universidad Autónoma Madrid.
36. Riera M., La Fuente L., Castanyer B., et al. Adherencia a los fármacos antirretrovirales medida por la concentración de fármacos y el recuento de comprimidos. Variables relacionadas con una mala adherencia. Med Clin 2002, 119:286-292.
37. Ruiz I., Orly A., Prada J.L., et al. Impacto de los factores demográficos y psicosociales en la no adherencia a los fármacos antirretrovirales. Enferm Infecc Microbiol Clin 2006, 24:373-378.
38. Tornero C., Cuenca A., Nolasco A., et al. Gasto farmacéutico en medicación antirretroviral y posibilidades de optimización. An Med Intern 2005, 22:575-578.
39. Ventura Cerdá J., Mínguez Gallego C., Fernández Villalba E., et al. Escala simplificada para detectar problemas de adherencia (ESPA) al tratamiento antirretroviral. Farm Hosp 2006, 30:171-176.
40. Ventura Cerdá J.M., Casado Gómez M.A., Escobar Rodríguez I., et al. Preferencias, satisfacción y adherencia con el tratamiento antirretroviral: estudio ARPAS (II). Farm Hosp 2007, 31:340-352.
41. Viciana P., Rubio R., Ribera E., et al. Estudio longitudinal de adherencia, satisfacción y efectividad del tratamiento antirretroviral administrado una vez al día, frente a dos veces al día, en una cohorte española de infectados por el VIH (estudio CUVA: cualquiera una vez al día). Enferm Infecc Microbiol Clin 2008, 26:127-134.
42. Lipsey M.W., Wilson D. Practical meta-analysis 2001, Sage, London.
43. 2 index?. Psychol Meth 2006, 11:193-206.
44. Aiken L.S., West S.G. Multiple regression: testing and interpreting interactions 1991, Sage, Newbury Park, CA.
45. Hedges L., Pigott T.D. The power of statistical tests in meta-analysis. Psychol Meth 2001, 3:203-217.
46. Duval S., Tweedie R. Trim and Fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 455-463.
47. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 4:1088-1101.
48. Egger M., Davey G., Schneider M., et al. Bias in meta-analysis detected by a simple graphical test. BMJ 1997, 315:629-634.
49. Buathong N., Hiransuthikul N., Tangwongchai S., et al. Association between depression and adherence to highly active antiretroviral therapy among adult HIV infected patients in Thailand. Asian Biomed 2009, 3:127-133.
50. Carrieri M.P., Leport C., Protopopescu C., et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immun Defic Syndr 2006, 41:477-485.
51. Heckman B.D., Catz S.L., Heckman T.G., et al. Adherence to antiretroviral therapy in rural persons living with HIV disease in the United States. AIDS Care 2004, 16:219-230.
52. Mills E.J., Nachega J.B., Buchan I., et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006, 296:679-690.
53. Protopopescu C., Raffi F., Roux P., et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother 2009, 63:599-606.
54. Puigventós F., Riera M., Delibes C., et al. Estudios de adherencia a los fármacos antirretrovirales. Med Clin 2002, 119:130-137.
55. Rudy B.J., Murphy D.A., Harris D.R., et al. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS 2009, 23:185-194. Adolescent Trials Network for HIV/AIDS Interventions.
56. D'Arminio Monforte A., Lepri A.C., Rezza G., et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients I. CO. N. A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000, 14:499-507.
57. Mocroft A., Youle M., Moore A., et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001, 15:185-194.
58. Carballo E., Cadarso-Suárez C., Carrera I., et al. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res 2004, 13:587-599.
59. Estévez C. Variables psicosociales asociadas a la adhesión terapéutica en pacientes con infección por el VIH en tratamiento antirretroviral de alta eficacia. 2000.
60. Remor E. Valoración de la adhesión al tratamiento antirretroviral en pacientes VIH+. Psicothema 2002, 14:262-267.
61. Penedo F.J., González J.S., Dahn J.R., et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. J Psychosom Res 2003, 54:271-278.
62. Remor E., Ulla S., Arranz P., et al. ¿Es la percepción de control un factor protector contra el distrés emocional en personas VIH+?. Psiquis 2001, 22:111-116.
63. Arrondo A., Sainz M.L., Andrés E.M., et al. Factores relacionados con la adherencia en pacientes infectados por el virus de la inmunodeficiencia humana. Farm Hosp 2009, 1:4-11.
64. Floridia M., Giuliano M., Palmisano L., et al. Gender differences in the treatment of HIV infection. Pharmacol Res 2008, 58:173-182.
65. Kumar V., Encinosa W. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatr Q 2009, 80:131-141.
66. Robison L.S., Westfall A.O., Mugavero M.J., et al. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008, 24:1347-1355.
67. Turner B.J., Laine C., Cosler L., et al. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003, 18:248-257.
68. Brañas F., Berenguer J., Sánchez-Conde M., et al. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med 2008, 121:820-824.
69. Carrieri P., Cailleton V., Le Moing V., et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001, 28:232-239.
70. Horne R., Cooper V., Gellaitry G., et al. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007, 45:334-341.
71. ¿Son adherentes los pacientes VIH+ de edad avanzada?. XII Congreso Nacional sobre Sida, "Una mirada al Mediterráneo" Organizado por SEISIDA, 20-22 mayo. Valencia 2009, J. Pasquau (Ed.).
72. Schneider J., Kaplan S.H., Greenfield S., et al. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med 2004, 19:1096-1103.
73. Ammassari A., Murri R., Pezzotti P., et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28:445-449.
74. Chesney M.A., Ickovics J.R., Chambers D.B., et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials. The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the adult. AIDS Care 2000, 12:255-266.
75. Cooper V., Gellaitry G., Hankins M., et al. The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study. AIDS Care 2009, 21:520-528.
76. Roca B., Gómez C.J., Arnedo A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect 1999, 39:141-145.
77. Cruess D.G., Minor S., Antoni M.H., et al. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women. J Pers Assess 2007, 89:277-290.
78. Malta M., Strathdee S.A., Magnanini M.M., et al. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008, 103:1242-1257.
79. Moatti J.P., Carrieri M.P., Spire B., et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000, 14:151-155.
80. Kalichman S.C., Rompa D., DiFonzo K., et al. HIV treatment adherence in women living with HIV/AIDS: research based on the information-motivation-behavioral skills model of health behavior. J Assoc Nurses in AIDS Care 2001, 12:58-67.
81. Mejorar la adherencia al tratamiento antirretroviral. Recomendaciones de SPNS/SEFH/GESIDA. Farm Hosp 2008, 52:349-357. Panel de expertos de la Secretaría del Plan Nacional sobre Sida (SPNS), Sociedad Española de Farmacia Hospitalaria (SEFH), Grupo de Estudio del Sida (GESIDA).
82. Simoni J.M., Frick P., Pantalone D.W., et al. Enhancing antiretroviral adherence: review of an emerging field. Best practices in behavioral management of chronic disease 2006, 70-95. Institute for Disease Management, Los Altos, CA. 2nd ed. J.A. Trafton, W. Gordon (Eds.).